[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Hospital Vall d'Hebron\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100644921","prov-mesh-prophylactic-ovarian-cancer-mesh-100644921",false,"NCT07676370","PROV-MESH: Prophylactic Ovarian Cancer MESH","A Multicenter Randomized Clinical Trial Comparing Prophylactic Mesh Placement Versus Primary Closure, With or Without Negative Pressure Wound Therapy, in Patients Undergoing Primary or Interval Cytoreductive Surgery for Ovarian Cancer","PROV-MESH","Inclusion Criteria:\n\n* Female patients diagnosed with ovarian carcinoma.\n* Undergoing primary cytoreductive surgery, interval cytoreductive surgery, or delayed cytoreductive surgery after six cycles of chemotherapy.\n* Surgical procedure performed through a midline laparotomy.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Surgery for recurrent ovarian cancer (secondary, tertiary, or subsequent cytoreductions).\n* Minimally invasive surgical approach.\n* Planned secondary cytoreductive surgery during the 24-month follow-up period.\n* Inability or unwillingness to comply with follow-up requirements.","FEMALE","18 Years",{"count":20,"type":21},152,"ESTIMATED","INTERVENTIONAL",[24],"NA","Incisional hernia is a common complication after midline laparotomy and may significantly impact quality of life, morbidity, and healthcare costs. Patients undergoing cytoreductive surgery for ovarian cancer are considered at increased risk due to extensive surgical procedures, nutritional status, and exposure to systemic treatments.\n\nThis prospective randomized clinical trial aims to evaluate whether prophylactic mesh placement during abdominal wall closure reduces the incidence of incisional hernia compared with conventional fascial closure in women undergoing cytoreductive surgery for ovarian cancer through a midline laparotomy. To control for the potential effect of negative pressure wound therapy (NPWT) on surgical site infection, participants will also be randomized to receive NPWT or standard wound dressing, resulting in four treatment arms.",[27],"Ovarian Cancer","RECRUITING","2026-06-24",{"date":31,"type":32},"2026-06-30","ACTUAL",{"date":34,"type":32},"2026-01-01",{"date":36,"type":21},"2030-12-31",{"name":38,"class":39},"Hospital Vall d'Hebron","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":58,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":40},"100469866","liver-transplantation-for-non-resectable-colorectal-liver-metastases-translational-research-100469866","NCT05398380","Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research","Clinical Impact of Molecular Biomarkers in Liver Transplantation for Non-resectable Colorectal Liver Metastases: Translational Research","Inclusion Criteria:\n\n1. Willing and able to provide written informed consent.\n2. Male or female, aged 18-70 years old inclusive at study entry.\n3. ECOG (Eastern Cooperative Oncology Group) 0 or 1.\n4. Histologically-proven primary colorectal tumor.\n5. Bilateral, limited at liver and non-resectable CRLM by consensus in Multidisciplinary Committee.\n6. Resection of primary colorectal tumor according oncological principles and adequate TNM stage.\n7. Time from primary colorectal tumor resection to transplant ≥ 12 months.\n8. Primary colorectal tumor stage ≤ T3N1. If time between primary tumor resection is ≥ 2 years, stage T4N0 or T4N2 is accepted.\n9. No signs of extrahepatic metastatic disease according to PET\u002FCT scan, CT and pelvic MRI.\n10. The patient has undergone systemic chemotherapy for a minimum of 3 months at the time of screening and maximum of 2 lines of fluoropyrimidine based chemotherapy combined or not with irinotecan or oxaliplatin associated or no not with targeted therapy based in molecular biomarkers.\n11. Demonstrated stability or partial regression of CRLM following RECIST criteria v 1.1., at minimum 3 months since the last treatment received and immediately prior to screening.\n12. CEA (Carcinoembryonic antigen) values ≤ 80 µg\u002FL immediately prior to screening.\n13. Adequate blood test regarding:\n\n    * Creatinine ≤1.25 x upper normal level or estimated glomerular filtration rate (eGFR) ≥60 mL\u002Fmin\u002F1.73m2 using following the Chronic Kidney disease epidemiology collaboration (CKD-EPI) formula.\n    * Platelets ≥80 × 109\u002FL\n    * Neutrophiles ≥ 2.5 × 109\u002FL\n14. Patients with hepatic failure after resection will be considered if it occurs as a consequence of an inadequate preoperative estimation of the functional volume that would have contraindicated the surgery. They should meet the inclusion criteria and none of the exclusion criteria.\n\nExclusion Criteria:\n\n1. Largest Lesion \\>5.5cm immediately prior to screening\n2. Patients with Lynch Syndrome\n3. BRAF mutation and\u002For primary tumor of microsatellite instability (MSI)\n4. Recurrence of primary tumor confirmed by colonoscopy or pelvic MRI within the last 12 months prior to screening.\n5. Previous or concurrent cancer in the last 5 years. Any cancer curatively treated 5 years prior to entry or treated basal cell carcinoma is permitted.\n6. Substance abuse, medical, psychological or social conditions that may interfere with the patient´s participation in the study or evaluation of the study results.\n7. Cardiac or pulmonary disease uncontrolled as contraindication for any surgical procedure.\n8. Active infection.\n9. Pregnant or breast-feeding patients\n10. Any reason why in the opinion of the investigator, the patient should not participate.","ALL","70 Years",{"count":51,"type":21},35,[24],"The patients with non-resectable colorectal liver metastases (CRLM) have always being considered a particular subgroup of CRLM in which the therapeutic approach, is focused on strategies that allow a potential surgery like neoadjuvant systemic treatments. But, the underlying biology that causes this particular profile of spread in a proportion of patients that always recur and progress in the liver has not been properly characterized from a biological point of view. Unfortunately, these patients finally develop liver metastasis not amenable for local treatments and become refractory to systemic treatments even without developing extrahepatic liver metastases. As a result, liver transplantation (LT) is a potential for patients without extrahepatic involvement and nonresectable CRLM. There are several studies that aims to evaluate if LT increases overall survival compared to best alternative care. To our knowledge, none of these studies incorporate objectives focused on the underlying tumor biology of this particular population and the development of focused strategies including a dynamic disease monitoring and targeted treatments for this particular population.The METLIVER trial will permit to expand the genetic studies to the whole complexity of metastatic lesions and a more precise evaluation of their genetic heterogeneity. Moreover, it will help to precise the type of genetic analyses on liquid biopsies that can be designed for patients that will unfortunately relapse mostly with lung metastases after LT. Our proposal will maximize the opportunity to produce an unprecedented knowledge on CRLM evolution and will provide new opportunities for relapsed patients.",[55,56,57],"Colorectal Cancer","Liver Metastases","Genetic Change",[59,60,61,62],"Liver Transplantation","Non-resectable colorectal liver metastases","Tumoral biomarkers","Translational research","2026-05-21",{"date":65,"type":32},"2026-05-22",{"date":67,"type":32},"2022-01-01",{"date":69,"type":21},"2026-12-31",{"name":38,"class":39},{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":48,"minAge":18,"maxAge":49,"enrollmentInfo":77,"targetDuration":79,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":40},"100391518","liver-transplant-combined-with-neoadjuvant-chemo-radiotherapy-in-the-treatment-of-unresectable-perihilar-cholangiocarcinoma-a-prospective-multicenter-study-100391518","NCT04378023","Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Perihilar Cholangiocarcinoma. A Prospective Multicenter Study.","Inclusion Criteria:\n\n* Willing and able to provide written consent form\n* Age ≤ 70 years-old\n* ECOG 0 or 1\n* Unresectable hCCA ≤3cm in radial diameter\n\nExclusion Criteria:\n\n* Those patients who have received chemotherapy or radiotherapy previously out of protocol\n* Liver, extrahepatic or lymph node metastases\n* Previous intent of surgical resection or percutaneous biopsy\n* Previous or concurrent cancer that is different in primary site or histology from adenocarcinoma, except cervical carcinoma in situ, localized prostate cancer, treated basal cell carcinoma, superficial bladder tumors (Ta, Tis, T1). Any cancer curatively treated 5 years prior to entry is permitted.\n* Infection no controlled",{"count":78,"type":21},34,"5 Years","OBSERVATIONAL","A prospective multicentre study which includes patients ≤ 70 years-old diagnosed of unresectable perihilar cholangiocarcinoma (pCCA) ≤3cm in radial diameter, without evidence of lymph node or distant metastases. Liver transplantation preceded by neoadjuvant radiochemotherapy will be performed in this selected group.\n\nThe primary endpoint will be overall survival at 1, 3, and 5 years post-transplant. The secondary endpoints will be: 1) recurrence-free survival at 1, 3 and 5 years post-transplant; 2) intention-to-treat survival of all patients included in the study at 1,3 and 5 years; 3) the rate of patients included in the study who are finally transplanted.",[83],"Unresectable Cholangiocarcinoma",{"date":85,"type":32},"2026-05-26",{"date":87,"type":32},"2020-04-24",{"date":89,"type":21},"2027-06-01",{"name":38,"class":39},""]